Company intelligence / Profile preview

Halscion

Duluth, Georgia, United Statesdrjudymorgan.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 3

Overview

Halscion developed and clinically tested a proprietary hydrogel scaffold device ("Celotres") designed to improve wound healing and reduce scar formation after surgical suturing. Multiple post-market clinical studies were completed evaluating safety and performance for both general scar outcomes and keloid recurrence prevention. The company is no longer active.

Therapeutic areas: Dermatology
Modalities: DeviceHydrogel-based drug delivery therapyBiomaterial scaffold
Industry: Therapeutic Medical Devices

Drug pipeline

4 assets

FemBloc

Phase 3

Indications: Permanent birth control

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Halscion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Halscion.

Explore the full profile